CD274 and non-small cell lung carcinoma: (40), analyzed the efficacy of pembrolizumab in two cohorts of patients with NSCLC and CNS metastases: cohort 1 included 37 patients with PD-L1 expression ≥ 1%, while cohort 2 included 5 patients with PD-L1 expression <1%.